Insights · the Brick 42 archive
Research notes and regulatory intelligence.
Migrated from the Brick 42 archive and re-voiced: BNCT and oncology research, oligonucleotide and regulatory movement, and the supply-side shifts that open generic markets.
BNCT & oncology
The TRANSBORO research stream.
From compound to clinic — what moves Boron Neutron Capture Therapy, and where the market and regulation follow. About the TRANSBORO project →
DiscoveryBoron: the new carbon in drug discoveryJan 2026
ChemistryNovel boron compounds for advanced cancer therapyApr 2026
DeliveryOptimizing liposomes for BNCT cancer treatmentApr 2026
DeliveryLipid nanoparticles: expanding BNCT's reach to tumorsMar 2026
ClinicalJapan leads with clinical BNCT for cancerMar 2026
ClinicalBNCT shows promise for high-grade central nervous system tumorsMar 2026
ImagingPrecision planning: PET boron imaging for BNCTDec 2025
DosimetryBoosting precision: a new BNCT dose measurement methodOct 2025
FundingEurope's multi-million-euro push for BNCT cancer therapyMar 2026
MarketBNCT market hits $3.1 billion — a new era for precision oncologyJan 2026
MarketBNCT market drivers and development challengesMar 2026
PolicyAccelerating BNCT's global adoption: regulatory and supply-chain keysApr 2026
GeographiesIndia's indigenous AD-BNCT: a global cancer breakthroughDec 2025
GeographiesTaiwan starts construction of a new BNCT centerDec 2025
Oligonucleotides & regulatory
Where the generic route opens.
RegulatoryWhat a draft guidance changes in a generic timelineMar 2022
OligonucleotidesMapping the oligonucleotide supply chain earlyApr 2023
Manufacturing & supply
What sets the cost and the timing.
ManufacturingOn-shore high-potency pharma manufacturing in the US and EUNov 2022
ExclusivityTerritory by territory: how generic entry is timedOct 2023
Migrated from the Brick 42 archive. Dates are each article's publication month; full articles move in as they are re-voiced.
Next
Reading is no substitute for an answer.
Put a molecule in and get a decision, or send the question straight to us.